Letter to Allergan plc image

The House of Representatives Committee on Oversight and Government Reform, October 3, 2017
By Trey Gowdy, Elijah E. Cummings, Dennis A. Ross, and Peter Welch, citing blog post by Rachel E. Sachs (Academic Fellow Alumna)


Read the full letter

From the letter:

On September 8, 2017, your company announced the trans r of six patents related to its Restasis drug to the Saint Regis Mohawk tribe. 1 The unconventional maneuver has received considerable criticism om the generic competitors challenging the drug's patents under the process Congress created to enable timelier review of such challenges.2 Allergan defended the transfer as a "sophisticated opportunity to strengthen the defense" of Restasis' patents.3 The sovereign status of Native American tribes adds time and complexity to contesting the status of the patents in question, because tribes may be immune om the legal claims generic drug makers use to challenge patents and bring less costly drugs to market more quickly.4 

Read the full letter here!

fda health law policy pharmaceuticals public health rachel sachs regulation